Lanzhou Foci Pharmaceutical released its semi-annual report for 2024, achieving a revenue of 0.499 billion yuan during the reporting period, a year-on-year decrease of 20.26%; the net income attributable to shareholders of the listed company was 36.0953 million yuan, a year-on-year decrease of 37.52%. The company stated that during the reporting period, sales revenue decreased due to factors such as the macroeconomic environment and intensified industry competition.
佛慈制药：上半年净利润同比下降37.52%
Lanzhou Foci Pharmaceutical: net income in the first half of the year decreased by 37.52% compared to the same period last year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated